- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Complex refractory fistulising Crohn disease Ulcerative colitis Crohn disease Chronic plaque psoriasis Hidradenitis suppurativa
- Meeting Date: March 2024
- Public Summary Document (PSD) March 2024 PBAC Meeting - (PDF 342KB)
- Public Summary Document (PSD) March 2024 PBAC Meeting - (Word 73KB)
Adalimumab – March 2024
Adalimumab: Injection 80 mg in 0.8 mL pre filled pen, Injection 80 mg in 0.8 mL pre filled syringe; Yuflyma®
Last updated
30 May 2025